dIRCAD and Department of Translational Medicine, Section of Neurology, "A. Avogadro", University of Eastern Piedmont "A. Avogadro", via Solaroli 17, Novara, 28100, Italy.
dIRCAD and Department of Translational Medicine, Section of Neurology, "A. Avogadro", University of Eastern Piedmont "A. Avogadro", via Solaroli 17, Novara, 28100, Italy.
Vaccine. 2014 Sep 29;32(43):5681-9. doi: 10.1016/j.vaccine.2014.08.016. Epub 2014 Aug 20.
"Inverse vaccination" refers to antigen-specific tolerogenic immunization treatments that are capable of inhibiting autoimmune responses. In experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), initial trials using purified myelin antigens required repeated injections because of the rapid clearance of the antigens. This problem has been overcome by DNA-based vaccines encoding for myelin autoantigens alone or in combination with "adjuvant" molecules, such as interleukin (IL)-4 or IL-10, that support regulatory immune responses. Phase I and II clinical trials with myelin basic protein (MBP)-based DNA vaccines showed positive results in reducing magnetic resonance imaging (MRI)-measured lesions and inducing tolerance to myelin antigens in subsets of MS patients. However, DNA vaccination has potential risks that limit its use in humans. An alternative approach could be the use of protein-based inverse vaccines loaded in polymeric biodegradable lactic-glycolic acid (PLGA) nano/microparticles (NP) to obtain the sustained release of antigens and regulatory adjuvants. The aim of this work was to test the effectiveness of PLGA-NP loaded with the myelin oligodendrocyte glycoprotein (MOG)35-55 autoantigen and recombinant (r) IL-10 to inverse vaccinate mice with EAE. In vitro experiments showed that upon encapsulation in PLGA-NP, both MOG35-55 and rIL-10 were released for several weeks into the supernatant. PLGA-NP did not display cytotoxic or proinflammatory activity and were partially endocytosed by phagocytes. In vivo experiments showed that subcutaneous prophylactic and therapeutic inverse vaccination with PLGA-NP loaded with MOG35-55 and rIL-10 significantly ameliorated the course of EAE induced with MOG35-55 in C57BL/6 mice. Moreover, they decreased the histopathologic lesions in the central nervous tissue and the secretion of IL-17 and interferon (IFN)-γ induced by MOG35-55 in splenic T cells in vitro. These data suggest that subcutaneous PLGA-NP-based inverse vaccination may be an effective tool to treat autoimmune diseases.
“反向疫苗接种”是指抗原特异性耐受原性免疫治疗,能够抑制自身免疫反应。在实验性自身免疫性脑脊髓炎(EAE),多发性硬化症(MS)的动物模型中,最初使用纯化髓鞘抗原进行的试验由于抗原迅速清除而需要重复注射。这个问题已经通过 DNA 疫苗得到解决,该疫苗仅编码髓鞘自身抗原或与白细胞介素(IL)-4 或 IL-10 等“佐剂”分子结合,以支持调节性免疫反应。基于髓鞘碱性蛋白(MBP)的 DNA 疫苗的 I 期和 II 期临床试验显示,在减少磁共振成像(MRI)测量的病变和诱导 MS 患者亚群对髓鞘抗原的耐受方面有积极结果。然而,DNA 疫苗有潜在风险,限制了其在人类中的应用。另一种方法可能是使用负载髓鞘少突胶质细胞糖蛋白(MOG)35-55 自身抗原和重组(r)IL-10 的蛋白质反向疫苗,以获得抗原和调节佐剂的持续释放。本工作的目的是测试负载髓鞘少突胶质细胞糖蛋白(MOG)35-55 自身抗原和重组(r)IL-10 的聚乳酸-乙醇酸(PLGA)纳米/微球(NP)负载的 PLGA-NP 对 EAE 小鼠的反向疫苗接种效果。体外实验表明,在封装到 PLGA-NP 中后,MOG35-55 和 rIL-10 均在数周内释放到上清液中。PLGA-NP 无细胞毒性或促炎活性,部分被吞噬细胞内吞。体内实验表明,皮下预防性和治疗性反向疫苗接种用负载 MOG35-55 和 rIL-10 的 PLGA-NP 显著改善了 C57BL/6 小鼠中用 MOG35-55 诱导的 EAE 病程。此外,它们降低了体外 MOG35-55 诱导的脾 T 细胞中中枢组织的组织病理学病变和白细胞介素 17(IL-17)和干扰素(IFN)-γ的分泌。这些数据表明,皮下 PLGA-NP 反向疫苗接种可能是治疗自身免疫性疾病的有效工具。